Ambit to provide overview of quizartinib drug candidate at Barclays Global Healthcare Conference

NewsGuard 100/100 Score

Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Barclays Global Healthcare Conference to be held at the Loews Miami Hotel in Miami Beach, FL, March 10-13, 2014.

Marcy Graham, Ambit's Executive Director of Investor Relations, will provide an overview of the Company and its lead drug candidate, quizartinib, at 9:00 a.m. ET on Wednesday, March 12, 2014, followed by a breakout session at 9:30am.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available until April 1, 2014 following the initial presentation webcast. 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI technologies can accurately identify cases of healthcare-associated infections